Lunai Bioworks

LNAI · NASDAQ

$0.515−$0.0003 (−0.06%)TodayMarket closed ·
Prev close $0.5153

Latest news

  • News

    12 Health Care Stocks Moving In Monday's Intraday Session

  • NewsAvi Kapoor

    Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

  • NewsRishabh Mishra

    Stock Market: Will S&P 500 Open Up or Down Today?

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releasePRNewswire

    Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

  • Press releasePRNewswire

    Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI

  • Press releasePRNewswire

    Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

  • News

    Lunai Bioworks Files Second Amended Complaint Against Six Registered Broker-Dealers And Two Broker-Dealer Principals As Defendants In U.S. District Court, Delaware

  • Press releasePRNewswire

    Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

  • News

    Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027

  • Press releasePRNewswire

    Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

  • Press releasePRNewswire

    Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

  • Press releasePRNewswire

    LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

  • NewsMohd Haider

    Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

  • Press releasePRNewswire

    Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

  • Press releasePRNewswire

    LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

  • Press releaseGlobe Newswire

    CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research

  • Press releaseGlobe Newswire

    Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against 'John Doe' 'Naked' Short-Sellers of Lunai Common Stock

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releasePRNewswire

    Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

  • News

    Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension—Intel, SAP, Lunai Bioworks In Focus (UPDATED)

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

  • Press releasePRNewswire

    Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releasePRNewswire

    Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releasePRNewswire

    Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • NewsAvi Kapoor

    Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.